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3. Summary of Study 
 
Individuals with severe mental illness (SMI) have much higher mortality rates from somatic 
causes than the general population, with life expectancies reduced by 10-30 years. The 
excess premature mortality has been shown to increase throughout the last decades, and is 
expected to continue rising well into the new millennium. As in the general population, 
cardiovascular disease (CVD) is the leading cause of death in patients with schizophrenia, 
bipolar disorder and severe depression, and contrary to the overall situation in western 
society, mortality from CVD in psychiatric patients is not declining. Previous studies have 
linked the increased cardiovascular risk in psychiatric patients to poor life-style and 
inadequate health services. Others have indicated that individuals with SMI may have a 
specific vulnerability for metabolic disturbances, intrinsic to the disease state itself. Finally, 
recent investigations have payed much attention to the liability of antipsychotics (APs) to 
cause weight gain and other metabolic side effects. However, results have been non-
conclusive, and the underlying mechanisms linking psychiatric and somatic disorders 
remain to be elucidated. 
 
The main object of the present studies was to gain more knowledge about CVD risk factors 
in patients with severe psychiatric disorders, with particular emphasis on the metabolic side 
effects of AP treatment. The first aim was to investigate the prevalence of known CVD risk 
factors in a representative sample of Norwegian patients, as compared with an age-matched 
reference group from the general population, and to determine the role of life style, using 
socio-demographic factors as a surrogate measure. The second aim was to assess the role of 
diagnosis, psychiatric symptom severity level, and the overall use of 
psychopharmacological treatment, by comparing CVD risk in subjects with schizophrenia 
and bipolar disorder. The third aim was to investigate whether increased levels of cardio-
metabolic risk parameters were associated with the commonly used AP agent olanzapine 
(OLZ), and how these were related to adiposity. The fourth aim was to investigate whether 
dysregulation of metabolic hormones was found in OLZ treated subjects, independent of 
body mass and body composition. 
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This report is based upon naturalistic data from the cross-sectional part of the Thematically 
Organized Psychosis Research (TOP) Study, carried out in joint collaboration between the 
University and University Hospitals of Oslo. Eligible patients were all those (1) registered 
in the psychiatric services of one of the University Hospitals in Oslo; (2) aged 18 to 65 
years; (3) meeting DSM-IV criteria for a major psychotic illness; and (4) being able and 
willing to give informed, written consent of participation. From October 2002 through July 
2006 a total of 414 patients were included, from all health care sectors of Oslo. For the 
different sub-studies, subjects from this main sample were selected according to the 
objectives of that particular investigation. Reference data were based upon the 2000/2001 
Oslo Health Study (HUBRO), including a total of 18,770 individuals from the general 
population of Oslo. 
 
Most known CVD risk factors were found to be approximately twice as prevalent in the 
study sample as in the general population, and young patients had the highest relative 
increase in risk. Differences in risk profiles between patients and references could not be 
explained by sociodemographic factors alone. Subjects with schizophrenia and bipolar 
disorder had approximately the same level of CVD risk factors. AP treatment with OLZ was 
associated with dyslipidemia, insulin resistance and increased levels of circulating leptin, 
independent of body mass and body composition. Women seemed to be particularly at risk 
for dysregulation of metabolism following OLZ treatment. 
 
In conclusion, cardio-metabolic risk was shown to be alarmingly high among subjects with 
SMI, independent of sociodemographic background, diagnoses, and psychiatric symptom 
severity. Dyslipidemia and insulin resistance were associated with specific AP treatment 
and could not be explained by weight gain alone.  
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5. Introduction  
 
5.1. Increased rates and causes of mortality in severe mental illness  
5.1.1. The pre-neuroleptic era 
Since the 17th century, there have been clinical reports in Western Europe on increased 
mortality among the mentally ill (Graunt, 1662). Pre-second world war psychiatry had no 
efficient treatment for schizophrenia or severe affective disorder. Patients, who could not be 
cared for by their families, were confined to lunatic asylums, under conditions that we, 
today, find deleterious and inhumane.  
 
During the first part of last century, two large Scandinavian studies were conducted on 
death rates and causes of death in the asylums (Ödegard, 1936; Alström, 1942). The authors 
made use of standardised mortality ratios (SMRs), calculated by dividing the observed 
mortality of a cohort by the expected mortality of an age- and gender-matched cohort of the 
general population, to measure differences in mortality. Both authors reported significantly 
elevated mortality among schizophrenia subjects, with SMRs between 2.1 and 4.0. The 
main causes of death were found to be tuberculosis and pneumonia, ascribed to the 
conditions of overcrowding, malnutrition, and poor hygienic conditions in the large 
institutions. A little later, Bleuler (1950) attributed most of the excess deaths in 
schizophrenia to “the indirect consequences of psychosis: refusal of food, intentional and 
unintentional injuries, suicide, tuberculosis and other diseases resulting from unhygienic 
ways of life”.  
 
5.1.2. The post-neuroleptic era 
After the Second World War, Western psychiatry was gradually transformed by new 
insights into the aetiology of mental disease and a more humane approach. Treatment was 
revolutionized by the introduction of drugs that provided efficient symptom control, such as 
lithium in 1948, chlorpromazine in 1952, and amitriptyline in 1960. From 1970 onwards, 
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deinstitutionalization gradually took place and the asylums were substituted by community 
based care.  
 
However, excess death rates among the mentally ill prevailed. In a meta-analysis of 
mortality studies among patients with schizophrenia between 1952 and 1995, Brown (1997) 
found that death rates were increased in every report included in the analysis, with an 
aggregate SMR of 1.5. These findings were replicated one year later in the systematic meta-
analysis by Harris & Barraclough (1998). Follow-up studies on schizophrenia cohorts 
conducted more recently, have indicated an increase in the overmortality among these 
patients (Brown et al, 2000; Ösby et al, 2000a; Ösby et al, 2000b). This tendency was 
confirmed in a recently published meta-analysis covering 37 studies from 25 countries, 
published between 1980 and 2006. In this study, the median all-cause SMR was 2.6, and the 
authors found that from 1970 through 1999, the differential mortality gap between 
schizophrenia patients and the general population had increased in a linear fashion (Saha et 
al, 2007). 
 
Although less comprehensive, parallel investigations have been performed on death rates in 
bipolar disorder, yielding similar results. In the meta-analysis by Harris & Barraclough 
(1998), and in two later follow-up studies by Angst et al (2000) and Ösby et al (2001) the 
reported SMRs in this group of patients was between 1.6 and 2.6.  
 
Poverty and infectious diseases are no longer major health problems in Western Europe, 
and causes of death in the mentally ill have shifted with that of the general population. In 
the cohorts from second part of last century examined by Brown (1997), Harris & 
Barraclough (1998), Brown (2000), and Ösby et al (2000), the authors estimated that 
approximately 40 % of the excess deaths in schizophrenia were due to suicide and 
unspecified violence, while 60 % were due to natural causes. Natural deaths were caused by 
the same broad spectrum of conditions as in the general population, and the largest single 
cause of death was CVD, in both males and females. The overall risk for cardiovascular 
death in schizophrenia was about 2-fold, and thus moderately increased, as compared to a 
15-20 fold risk for suicide, but CVD still accounted for the largest total number of excess 
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deaths. In addition, the risk of cardiovascular death was clearly increasing throughout the 
study period (Ösby, 2000). For bipolar disorder, Harris & Barraclough (1998), Ösby (2001), 
and Angst et al (2002), found the same pattern of mortality causes, with circulatory diseases 
being responsible for the highest number of excess deaths, followed by suicide. 
 
5.1.3. The last decennium  
Since 1995, major improvements in the pharmacotherapy of mental illness have occurred 
with the introduction of second generation antipsychotics (SGAs), along with new 
antidepressants and mood-stabilizers. Accordingly, adherence to treatment has been 
facilitated, and many patients have been helped to a better integration in society. Despite 
these progresses, mortality rates in psychiatric populations remain exceedingly high. In a 
recent study across eight American states, Colton & Manderscheid (2006) showed that life 
expectancy for people with SMI was 20-30 years shorter than for the general population, 
with cardiovascular disease being the leading cause of death. In accordance with this, Enger 
et al (2004) reported that in the USA between 1995 and 1999, treated schizophrenia 
outpatients had a 5-fold increased risk of death by myocardial infarction. The situation 
seems to be about the same in Western Europe. Thus, a population based study, including 
almost all individuals with psychosis or severe mood disorder in the United Kingdom 
between 1987 and 2002, demonstrated a 3-fold increased risk of CVD death in patients 
below 50 years, and a 2-fold increased risk in patients above 50 years of age. (Osborn et al, 
2007). 
 
5.2. Causality factors  
The precise origin of the raised vulnerability to CVD in the mentally ill has been sought for, 
but remains elusive and, most likely, cannot be attributed to a single mechanism. At present, 
most authors agree that the causality is multifactorial (Wildes et al, 2006), and the issue is 
being pursued along several lines of investigation. 
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 5.2.1. Vulnerability to lifestyle hazards   
According to a twin study of mortality in schizophrenia by Kendler (1986), the pattern of 
natural deaths in this disorder could not be due to the disease state alone, but was better 
explained by altered exposure to environmental risk factors. People with severe mental 
disorders are generally considered to have an illness-related vulnerability of adopting 
deleterious lifestyles (Ösby et al, 2000). Exposed to the general health threats of modern 
society, these patients are prone to excessive smoking, alcohol and drug abuse, poor diets, 
and lack of physical exercise (McCready et al, 2003; Davidson et al, 2001; Katon et al, 
2003). Western society today is characterized by its “obesogenic” conditions, implicating 
that easy access to food and reduction in energy expenditure have made obesity and related 
disorders a major threat to public health (National Task Force, 2000; Bell et al, 2005). 
Allison et al (1999), and Homel et al (2001) were among the first to report on an increased 
prevalence of obesity in subjects with schizophrenia versus controls, also demonstrating 
that body mass in schizophrenia patients, females in particular, was dramatically increasing. 
This tendency has later been confirmed in several studies (McEvoy et al, 2005) and is now 
often referred to as “an epidemic within an epidemic” (Newcomer & Hennekens, 2007).  
 
5.2.2. Insufficient medical care  
Mortensen & Juel (1993) and Ösby et al (2000) ascribe the increase in “avoidable deaths” 
among schizophrenia patients to the rapid changes that have taken place within psychiatric 
care over the last 30 years, with long term inpatient units being replaced by outpatient 
treatment facilities, and a dramatic reduction in hospital beds assigned to this group of 
patients. 
  
People with SMI frequently have an altered notion of somatic symptoms and a decreased 
ability to seek medical help. Unfortunately, somatic issues are often given low priority 
within the psychiatric services, while psychiatric patients get low priority within the somatic 
medical care system (Marder et al, 2004; Newcomer & Hennekens, 2007). Somatic 
disorders in patients with SMI are frequently not diagnosed and primary treatment 
neglected. Brown et al (2000) found that in the U.K., death rates of “avoidable” somatic 
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causes were nearly five times increased in schizophrenia, while Nasrallah et al (2006) 
reported that in the USA a large proportion of schizophrenia patients did not receive 
medical treatment for conditions such as diabetes (30 %), hypertension (62 %), and 
dyslipidemia (88 %). Also, secondary prevention is often inadequate. Based upon findings 
from a nation wide study on the quality of post myocardial infarction care, Druss et al 
(2007) concluded that follow-up treatment was deficient among patients with mental 
disorders, and could explain a substantial portion of the highly increased mortality found in 
this group. The decline in mortality from CVD in the general population during the last 
decades is considered to be largely an effect of improved diagnosis and treatment 
(Lichtenstein et al, 2006). There are thus strong indications that insufficient medical care is 
a major cause of the increasing overmortality seen in people with SMI (Newcomer & 
Hennekens, 2007).  
 
5.2.3. Risk factors intrinsic to mental illness  
There is, however, evidence that some CVD risk factors may be inherent to psychiatric 
illness itself. Long before the dawn of the “obesogenic society”, metabolic disturbances 
were associated with SMI. Sir Henry Maudsley, in his “Pathology of the Mind”, 
commented that “Diabetes is a disease which often shows itself in families in which 
insanity prevails” (Maudsley, 1879). During the first part of last century, specific alterations 
of energy metabolism were assumed to be an intrinsic factor of psychotic illness (Kraepelin, 
1921; Bleuler, 1930). Dysregulation of vegetative functions was often linked to “body 
types” (Kretschmer, 1936), and studies were performed showing abnormal glucose 
tolerance in patients with “dementia preacox and manic depressive insanity” (Raphael & 
Parsons, 1921; Meduna, 1942; Langfeldt, 1952). Some imbalance in the sympathetic versus 
the para-sympathetic nervous system was presumed. 
 
Recent studies seem to confirm that type 2 diabetes is more common in schizophrenia 
subjects (Henderson & Ettinger, 2002; Henderson, 2005; Ryan & Thakore, 2002; Thakore, 
2005; Cohen et al, 2006), as well as in their otherwise healthy first-degree relatives 
(Mukherjee et al, 1989). There are also indications that drug-naïve individuals with 
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schizophrenia may have alterations in body composition, with larger amounts of visceral fat 
(Thakore et al, 2002), and more insulin resistance (Ryan et al, 2003), than matched 
controls. The reason for this, however, remains uncertain. One proposed hypothesis is that a 
common genetic vulnerability, or perinatal adversities, may dispose for insulin resistance as 
well as mental disorder. Alternatively, metabolic dysregulation is thought to be the result of 
disease specific stress resulting in chronic hyperactivity of the hypothalamic-pituitary-
adrenal (HPA) axis.  
 
Interestingly, a recent Finnish, register based study showed that the incidence of 
schizophrenia is substantially decreased in patients with type 1 diabetes, a finding which is 
not easily explained (Juvonen et al, 2007). The authors speculate that some factors 
associated with type 1 diabetes may modify the phenotype or the clinical picture of 
psychosis in the direction of affective disorder, but more research is clearly needed. 
 
5.2.4. Adverse effects of treatment  
The “cures” of the pre-neuroleptic era caused many deaths. According to Bleuler (1978), 
treatment accounted for 17 % of the total mortality in a schizophrenia cohort followed from 
1942 to 1965. The mortality following leucotomy was from 1-18 %, varying among centres, 
dependent on the operation method, and skills of the operator (Swayze et al, 1995; Ögren et 
al, 2007). Insulin coma had a mortality of approximately 1%, and Cardiazole and ECT 
induced convulsions caused significant morbidity due to fractures, at least before the 
introduction of curare (Henderson & Gillespie, 1952). Not included in these crude figures, 
are the immense sufferings of the patients and their families in a period when no effective 
treatment was available. 
 
With the introduction of chlorpromazine in 1952, the treatment of schizophrenia was 
revolutionized. However, improvement of psychosis often came at the price of 
extrapyramidal symptoms (EPS) and tardive dyskinesia (TD), sometimes causing more 
subjective suffering to patients than the disorder itself, and making adherence to treatment a 
great challenge. When the second generation antipsychotics (SGAs) became available in the 
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1990ies, the risk of EPS and TD fell dramatically. In addition, according to some authors, the 
new drugs had better effect on negative symptoms, depression, and cognition (Davies et al, 
2003). They were therefore enthusiastically welcomed for providing patients a better quality 
of life, and soon gained large access to the market. 
 
However, with the new drugs, an old problem was exacerbated. Obesity as a result of 
pharmacological treatment had been noticed since the 1950ies (Planansky, 1958), but with 
the turn of the century, drug induced weight gain became a major obstacle in the treatment 
of severe mental disorders. In two meta-analyses addressing this issue, Allison et al (1999) 
and Allison & Casey (2001) concluded that most neuroleptics are potentially obesogenic, 
but that there are large differences between agents, with clozapine (CLZ) and olanzapine 
(OLZ) inducing most weight gain. These findings have been replicated in a multitude of 
other studies, causing growing concern about the obesity related, cardiovascular hazards 
associated with antipsychotic treatment (Meyer, 2001; American Diabetes Association, 
2004, Nasrallah et al, 2004; Newcomer, 2005; Fenton & Chavez, 2006). 
 
In addition to the hazards of EPS and weight gain, APs have been shown to increase the risk 
of serious ventricular arrhythmias. In one study on classical neuroleptics, Ray et al (2001) 
showed that patients prescribed moderate drug doses had large relative and absolute 
increases in the risk of sudden cardiac death, and that risk was even higher in users who 
already had CVD. There are indications that some SGAs also have proarrhythmic properties 
(sertindol, ziprazidone), but this is of little clinical importance (Drici et al, 1998; Lindström 
& Levander, 2006).  
 
Up till now, it has not been possible to link any particular AP agent with increased CVD 
morbidity or mortality. Osborn et al (2007) concluded that the excess death rates found 
among mentally ill people in their study, could not wholly be explained by smoking or 
social deprivation. Nor could they be explained by the use of AP medication alone. None 
the less, patients prescribed APs seemed to be at even greater risk than those who were not 
prescribed these agents.  
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5.3. The metabolic syndrome  
 The association of obesity with metabolic disturbances and vascular disease is not new. By 
the year 1761, Morgagni had already discovered the co-occurrence of visceral fat 
accumulation, hypertension, abnormal metabolism and atherosclerosis (Enzi et al, 2003). 
The notion of a syndrome linking these parameters then went unnoticed until the 20th 
century, and was first really put on the medical agenda with the coining of the term 
“syndrome X” by Reaven (1988). Eventually, this rubric evolved into what is now generally 
known as the metabolic syndrome (MetS). 
 
Primarily as a result of the increasing prevalence of obesity, diagnosis and management of 
the MetS has become an important medical challenge (Expert Panel of Detection, 2001; 
Bloomgarden, 2004; Eckel et al, 2005; Grundy et al, 2005). The MetS is best seen as a 
physiological change with clustering of interrelated metabolic risk factors for developing 
type 2 diabetes and CVD, as well as a variety of other disorders. Non-diabetic individuals 
with the syndrome have been shown to have a 2-3 fold increase in cardiovascular, and a 1.5-
increase in all-cause mortality, after adjustments for age, smoking and blood cholesterol 
levels have been made. When the syndrome is complicated with diabetes, mortality is even 
higher (Hu et al, 2004).  
 
However, the MetS has had its adversaries (Johnson & Weinstock, 2006). In a joint 
statement from the American Diabetes Association and the European Association for the 
Study of Diabetes, Kahn et al (2005) argues that the syndrome is imprecisely defined, based 
on somewhat arbitrary cut-off values for the various risk factors. In addition, the authors 
emphasize that the symptoms associated with the syndrome have an uncertain common 
pathogenesis, and that there is doubt whether the cluster conveys risk beyond the risk 
associated with its individual components.  
 
The International Diabetes Federation strongly argued against this critic (Zimmet & Alberti, 
2005), and despite an ongoing debate, the concept has gained widespread use as a screening 
tool, mainly because it is low cost, easy to apply in clinical practice, and is generally 
considered to have high predictive value (Alberti, et al, 2005). Several expert groups have 
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attempted to set forth simple diagnostic criteria. There is now general agreement on the 
main metabolic components of the syndrome being elevated blood pressure, atherogenic 
dyslipidemia, and elevated plasma glucose (Grundy et al, 2005). There is, however, still 
discussion of whether abdominal obesity or insulin resistance may be the essential cause of 
the clustered metabolic disturbances (Balkau et al, 2002; Reaven, 2002). Although 
hypothesis on pathophysiology need to be harmonized, clarifying the relative importance of 
environmental exposure versus genetic vulnerability, the unifying point may be that insulin 
resistant individuals often have abnormal (upper-body) fat distribution, while adipose tissue 
in obese individuals often is insulin resistant. Thus, most current definitions have included 
the presumed underlying risk factor of abdominal obesity in the definition of the syndrome 
(Grundy et al, 2005).  
 
It is important to emphasize that obesity in itself is only a weak risk mediator for type 2 
diabetes and CVD. Metabolic risk is stronger associated with body composition than with 
body mass, and obesity can be subdivided into a group of centrally localized body fat, 
where much fat is stored in intra-abdominal, visceral depots, and a peripheral gluteofemoral 
subgroup. The former carries the majority of the risk of obesity related diseases (Bjørntorp 
& Rosmond, 2000). 
 
5.3.1. Definition 
Several working definitions of the MetS are being employed, thus complicating the 
comparison of prevalence and impact between studies. Most current reports within the field 
of psychiatry base their analyses on the definition proposed by the National Cholesterol 
Education Program, Adult Treatment Panel III (NCEP ATP III) (Expert Panel of Detection, 
2001), or on the ATP III version revised by the American Heart Association (AHA) and the 
National Heart, Lung, and Blood Institute (NHLBI) in 2003 (Grundy et al, 2005). For 
establishing the diagnosis according to the AHA/ NHLBI definition of MetS, at least three 
out of five of the following criteria must be present: (1) FPG  5.6 mmol/l = 100 mg/dl, or 
on drug treatment for elevated glucose; (2) TG  1.7 mmol/l = 150 mg/dl, or on drug 
treatment for elevated TG; (3) HDL-C < 1.04 mmol/l = 40 mg/dl (men) and < 1.29 mmol/l 
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= 50 mg/dl (women), or on drug treatment for reduced HDL-C; (4) Systolic BP  130 
mmHg or diastolic BP  85 mm Hg, or on antihypertensive drug treatment; and (5) Central 
obesity: waist > 102 cm = 40 in. (men) and > 88 cm = 35 in. (women). 
 
5.3.2. Prevalence of the metabolic syndrome in patients with severe mental 
illness 
The first report on a raised prevalence of MetS in schizophrenia was published by 
Heiskanen et al (2003). It was soon followed by others (Basu et al, 2004; Cohn et al; 2004). 
Although these pioneering studies were small-sized and suffering from the lack of reference 
groups, they opened up a new field of interest, by suggesting a 2-4 times raised prevalence 
of MetS among patients, and indicating a high occurrence at much younger ages than in the 
general population (Cohn et al, 2004). The issue was pursued in the Clinical Antipsychotic 
Trials of Intervention Effectiveness (CATIE) Study (Lieberman et al, 2005). Parallel to the 
publication of Paper I in the present thesis, McEvoy et al (2005) reported on baseline 
findings from 686 chronic schizophrenic patients in the CATIE Study, where the prevalence 
of MetS was over 35 % in males and over 50 % in females. At approximately the same 
time, Saari et al (2005) found that schizophrenia patients from the Northern Finland 1966 
Birth Cohort Study had a 4-fold risk of MetS. In addition, the data indicated that risk was 
particularly increased in young individuals.  
 
5.4. Introduction to the sub-studies  
5.4.1. Risk across populations and the role of sociodemography (Paper I) 
Life style related disorders, such as obesity, MetS, and type 2 diabetes are known to vary 
across continents, with much higher prevalences in the USA than in Europe (Balkau et al, 
2002; Ford et al, 2002). At the onset of the present study, reports on CVD risk in 
psychiatric populations were scarce and predominantly based on American samples of 
chronic schizophrenia patients. On this background, we decided that a prevalence study of 
CVD risk factors in a more representative sample of Norwegian patients with SMI would be 
a good starting point for this thesis.  
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Inherent metabolic risk depends closely on biological variables such as age, sex, and 
ethnicity, while amenable lifestyle risk is linked to cultural and socioeconomic factors (Hu 
et al, 2004). CVD risk may change in the course of a few years with altered life style in any 
given population (Strand & Tverdal, 2004). As in the rest of the Western world, overweight, 
type 2 diabetes, and insufficient physical activity are increasing health problems in Norway 
(Midthjell et al, 1999; Graff-Iversen et al, 2007). Despite this worrisome fact, there has 
been a decline in cardiovascular deaths over the last four decades (Norwegian Institute of 
Public Health; Jenum et al, 2007). This is largely the product of two factors: important 
progress in medical care and intense campaigns to improve public health related behaviour. 
In the general population, these campaigns have been successful in reducing the rates of 
smoking, hypertension and high cholesterol levels.   
 
However, public health information is known to be more effective with some sections of the 
population than others, and well educated individuals are the most likely to adjust their 
lifestyle according to recommendations from the health authorities. In Norway, the variation 
in health risk factors is larger within the capital of Oslo than among any other region of the 
country, reflecting a larger variation in educational levels, as well as in genetic, cultural, and 
socioeconomic conditions. We therefore wanted to compare CVD risk in a patient sample 
drawn from the city of Oslo, with reference data from the general population of the same 
geographical area within the same time span. A compelling question would be whether 
sociodemographic differences between the two cohorts could explain any differences found. 
 
The choice of sociodemographic factors to investigate was based upon previous studies. In 
addition to age and sex, ethnicity is highly predictive of raised CVD risk (Chaturvedi, 
2003), and increased prevalences of obesity and type 2 diabetes has previously been 
demonstrated in immigrant groups living within the urban society of Oslo (Jenum et al, 
2005). As to socioeconomic differences, educational levels has previously been shown to 
impact upon health related behaviour in a more consistent fashion than income, resulting in 
a significantly lower morbidity and higher life expectancy among well educated individuals 
living in Norway. Finally, previous population studies have shown marital status to be of 
importance, and living single to be associated with a poorer lifestyle and higher CVD risk, 
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at least in males (Strand & Tverdal, 2004). On this basis we decided to include data on 
ethnicity, marital status and level of education as explanatory variables in our investigation, 
in addition to age and gender. 
 
5.4.2. Cardiovascular risk in bipolar disorder versus schizophrenia (Paper II) 
At the time when we started our investigation, there were few reliable reports on somatic 
risk factors in bipolar patients to be found, although cardiovascular mortality had been 
reported to be approaching that of schizophrenia (Harris & Barraclough, 1998; Angst et al, 
2000; Ösby et al, 2001; Kupfer, 2005). Some authors had described elevated rates of 
obesity (Elmsie et al, 2000; Fagilioni et al, 2002; McElroy et al, 2002; Keck & McElroy, 
2003) and diabetes (Cassidy et al, 1999) in bipolar disorder, and other reports on 
hypertension (Johannessen et al, 2006), and the MetS (Fagilioni et al, 2005; Yumru et al, 
2006) were published in parallel to our enquiries. Most of the previous studies, however, 
were on highly selected samples, without normal reference groups; and only Johannessen et 
al (2006) had compared the risk prevalence in bipolar and schizophrenia patients.  
Interestingly, during the progress of our work, an excellent study was published, showing 
obesity to be significantly associated with mood disorders in a sample of nationally 
representative US adults, particularly in those segments of the population where the overall 
rates of obesity were lowest, such as young, highly educated, white females (Simon et al, 
2006). In addition, depression was shown to increase the risk of developing insulin 
resistance and type 2 diabetes (Timonen et al, 2005; Enger et al, 2006). 
 
Patients with bipolar disorder are generally less impaired, clinically, cognitively and 
socially, than patients with schizophrenia, and would therefore be considered more capable 
of adopting a healthy life style. Furthermore, antipsychotics, known to induce weight gain, 
are less widely used in this group of patients compared to patients with schizophrenia. Such 
circumstances should favor a more beneficial CVD risk profile in people with bipolar 
disorder. On this background, we decided to compare a representative sample of bipolar 
versus schizophrenia patients on the prevalence of CVD risk factors, as well as on 
sociodemographic variables, psychiatric symptom severity and drug use. In addition, both 
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groups were compared with a gender matched and age adjusted reference group from the 
general population of Oslo. 
 
5.4.3. Metabolic side effects of antipsychotic treatment (Paper III) 
Before and during the progress of our investigation, numerous prospective, randomized 
studies and register based population studies have reported on different liabilities to cause 
metabolic side effects among APs (Sernyak et al, 2002; Koro et al, 2002; Tandon & 
Gibson, 2003; McQuade et al, 2004; Zhang et al, 2004; Nasrallah, 2006; Olfson et al, 2006; 
Fleischhacker & Widschwendter, 2006). However, such differences have not been readily 
demonstrated in studies of patients receiving treatment as usual (Smith et al, 2005; Cohen et 
al, 2006; Remington, 2006). Actually, we found only one report linking a raised prevalence 
of the MetS to the use of a specific drug, namely CLZ (Lamberti et al, 2006). This study 
was clearly performed on a highly selected patient sample; and the investigators did not 
have access to a proper control group, but used only references to general population data.  
 
Most previous investigations had focused on the obesogenic properties of SGAs, causing 
subjective distress and often leading to non-compliance with treatment (Weiden et al, 
2004). Meta-analyses had shown CLZ and OLZ to induce more weight gain than other APs 
(Allison et al, 1999; Allison & Casey, 2001). However, this has not been consistently found 
in clinical treatment studies (Smith et al, 2005; de Leon et al, 2007). Other studies indicated 
that APs such as CLZ and OLZ, besides weight gain, could induce metabolic disturbances, 
in particular insulin resistance and glucose intolerance, independent of obesity (Newcomer 
et al, 2002; Henderson et al, 2005; Ader et al, 2005; Wang et al, 2006; Houseknecht et al, 
2007; Sacher et al, 2007). The question of whether dyslipidemia could also be a direct 
effect of AP treatment had been much discussed, but was as yet unsolved (Meyer & Koro, 
2004). To further elucidate these issues, we set out to compare the distribution of obesity 
and related metabolic parameters in a naturalistic sample of young outpatients on strict 
monotherapy with different AP agents, using currently drug free patients as a control group. 
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5.4.4 Hormonal dysregulation following antipsychotic treatment (Paper IV)  
Increased appetite, has been proposed as a mechanism for AP induced weight gain and 
MetS, in addition to alterations in body composition, energy expenditure, and glucose 
metabolism, but the molecular pathways leading to such effects are not well understood 
(Zhang et al, 2004; Graham et al, 2005; Kim et al, 2007; Meltzer, 2007). Drug interaction 
with several neurotransmitter receptors has been hypothesized. Since APs have complex 
pharmacological actions and interact with virtually every type of biogenic amine receptor in 
the brain, a large number of candidate receptors have been proposed. In a study from 2003, 
Kroetze et al showed that the most robust predictor of a drug’s propensity to induce weight 
gain was its affinity for the H1-histamine receptor (H1R). APs with high H1R affinity are 
typically drugs reported to be obesogenic, such as CLZ and OLZ, while APs with low H1R 
affinity are those shown to induce minimal weight gain, such as ziprazidone and 
aripiprazole. 
 
Kim et al (2007) recently demonstrated that CLZ and OLZ, through high H1R receptor 
antagonism, cause potent and selective stimulation of the intra-neuronal enzyme adenosine 
monophosphate (AMP)-activated protein kinase (AMPK) in the hypothalamus of rats, 
thereby blocking the action of the anorexigenic hormone leptin, with resulting hyperphagia 
and weight gain. The study also showed that CLZ reverses the suppressive effect of insulin 
on AMPK in the hypothalamus of research animals, causing central insulin resistance, 
which, besides obesity, has been proposed as the core pathophysiology of MetS (Reaven, 
2002).  
 
However, findings on the hormonal regulation of metabolism in rats are not directly 
applicable on humans. To further elucidate these questions, studies on real life patients are 
required, but hormonal resistance is not readily measured in clinical samples. Results from 
studies using surrogate measures need to be interpreted with care and a great variety of 
confounding variables must be accounted for. As in unmedicated healthy subjects, adiposity 
has been shown to be a main predictor of insulin resistance in AP treated patients, 
explaining at least one third of the variance in insulin sensitivity (Haupt et al, 2007). The 
same is probably true for resistance to leptin (Meier & Gressner, 2004). Samples should 
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thus be rigorously controlled for adiposity measurements, as well as for age, gender, and 
ethnicity, ideally also for smoking behaviour, exercise level, and diet. When comparing 
drug effects between treatment groups, these should be matched for psychiatric severity 
scores, and an unmedicated patient group should be included to control for the impact of 
SMI itself. Most previous naturalistic studies have failed to do so. In addition, the 
importance of co-medication with independent metabolic side effects has often been 
neglected.  
 
Given all these obstacles, at the time of our investigation, only a few clinical studies had 
given indications of a direct effect of OLZ on insulin resistance in human subjects, 
independent of body mass (Newcomer et al, 2002; Henderson et al, 2005, Sacher et al, 
2007). On the other hand, studies of APs on sensitivity to leptin had yielded conflicting and 
non-conclusive results (Melkersson & Hulting, 2001; Hägg et al, 2001; Haupt et al, 2005; 
Atmaca et al, 2003; Graham et al, 2005; Henderson et al, 2005; Smith et al, 2005; 
Hosojima et al, 2006). To further elucidate the issue of differential AP effect on resistance 
to insulin and leptin in humans, we chose to study variations in a variety of surrogate 
measures in a sample of patients naturally matched for most confounding variables, using 
unmedicated patients as a control group. 
 
5.5. Aims of the thesis 
 
Overall aim 
The overall aim of the thesis was to gain more knowledge about CVD risk in patients with 
SMI, with emphasis on metabolic side effects of AP treatment.  
 
Subaims 
To investigate the prevalence and distribution of CVD risk factors in a sample of 
pharmacologically stable out-patients with SMI from the city of Oslo, and compare their 
risk profile to that of the general population. Furthermore, to examine whether differences 
in socio-demographic variables could explain differences in the risk profile between the 
patient and the reference group (Paper I).    
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To investigate the prevalence of smoking and metabolic disturbances in bipolar disorder 
and compare it with schizophrenia in a representative sample of patients under naturalistic 
conditions. Furthermore to compare the prevalence of CVD risk factors in each diagnostic 
group with the general population (Paper II). 
 
To compare the distribution of obesity and other metabolic disturbances in a naturalistic 
sample of patients on OLZ (or CLZ) monotherapy with patients on monotherapy with other 
APs, considered less liable than OLZ and CLZ to induce weight gain, and with currently 
drug free patients. Furthermore to investigate if metabolic risk factors linked to any specific 
AP treatment appeared independent of body mass (Paper III).  
 
To test the hypothesis that patients receiving OLZ had signs of increased resistance to leptin 
and insulin actions compared to patients receiving other AP agents, and patients receiving 
no AP treatment.  Furthermore, to investigate if this coincided with signs of hepatic insulin 
resistance, as marked by a decreased level of SHBG, and whether any gender specific 
differences in hormonal regulation were present among treatment groups (Paper IV).  
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6. Materials and Methods 
 
6.1. The Thematically Organized Psychosis Research (TOP) Study 
The Oslo TOP Study is a large, multisite research study, carried out by the University of 
Oslo in joint collaboration with all four University Hospitals in Oslo on the basis of the 
specialist psychiatric services. Patients with SMI from all health care sectors of Oslo are 
included, the main diagnostic groups being schizophrenia and bipolar disorder. Inclusion of 
patients is ongoing. In this thesis, data are based on patients included in the study from 
start-up in October 2002 through July 2006. The study design is naturalistic, with a 
translational approach. Thus, a number of biological and clinical characteristics of SMI are 
investigated in order to gain more knowledge about the underlying pathophysiological 
mechanisms of disease.  
 
The inclusion area covers practically the whole city of Oslo, with a total of 550.000 
inhabitants, living in urban and suburban parts of the capital. The treatment system is 
catchment area based and publicly funded. Patients are referred from primary care. The core 
basis of the psychiatric specialist treatment system is subsector catchment area-based 
outpatient units, with the addition of acute, intermediate and long treatment units. Eligible 
patients were all those meeting study criteria and giving informed written consent of 
participation. The Regional Committee for Medical Research Ethics and the Norwegian 
Data Inspectorate approved the study, and the biobank was approved by the Ministry of 
Health. 
 
6.1.1. Subjects 
Inclusion criteria for the TOP Study are broad, consisting of (1) being registered in the 
psychiatric services of any of the 4 University Hospitals in Oslo; (2) aged 18 to 65 years; 
(3) meeting the DSM-IV criteria for any major psychotic or bipolar disorder; (4) 
understanding and speaking a Scandinavian language; (5) having no history of severe head 
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trauma or neurological disease; and (6) having an Intelligence Coefficient (IQ) score over 
70. 
 
Patients are included mainly from the outpatient units of each health care sector, but also 
from intermediate and long treatment units. Patients in acute ward treatment are considered 
not currently capable of participation. These patients are instead approached after release 
from hospital, when their mental condition is stabilized. All participants are invited into the 
study by the clinician responsible for their treatment. Those willing to participate receive 
thorough information of the study aims and procedures from one of the PhD students 
responsible for the assessments, all of them trained psychologists or psychiatrists. The 
inclusion procedure itself is divided into several sessions and in total comprises eight hours 
or more of assessment, including clinical interviews, a physical examination and 
neuropsychological testing. The interviews take place partially at the patient’s regular 
treatment unit, and partially at Ulleval University Hospital. Patients with problems using 
public means of communication are offered free transport by taxi.  
 
Throughout the study period of this thesis, a total of 414 patients were included, 210 men 
and 204 women. Median age for both genders was 32 years, ranging from 17-67 years. 
Three hundred forty five (83 %) subjects were Caucasian, while, of the 69 (17 %) Non-
Caucasians, the largest subgroup, 32 subjects (8 %), had origins from the Indian 
subcontinent. Of the entire sample, 51 % (121 men, 91 women) had diagnoses of 
schizophrenia, schizoaffective or schizophreniform disorder (here called schizophrenia), 
while 30 % patients (49 men, 76 women) had diagnoses of bipolar I, bipolar II, or bipolar 
NOS disorder (here called bipolar disorder). The rest of the sample, 19 % (40 men, 37 
women), had diagnoses of psychosis NOS, delusional disorder, or severe depression with 
psychotic symptoms (here called other psychotic disorders). Comorbid DSM-IV diagnoses 
of abuse or addiction to alcohol/ illicit drugs were found in 24 % of the patients (60 men, 40 
women), a figure corresponding fairly well with other studies, where drug abuse has been 
reported in 15-77 % of patients with psychotic disorders (Ringen et al, in press).  
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Duration of illness, estimated from first contact with the specialized psychiatric service, was 
in the range of 0-48 years for the entire sample, with a median duration of 3 years. At the 
time of assessment, 346 (84 %) of the subjects were outpatients, while 67 (16 %) subjects 
were hospitalized. Total PANSS scores of the entire sample ranged from 30-123, with a 
median value of 53, while symptom GAF scores ranged from 15-92, with a median value of 
45, and function GAF scores ranged from 22-85, with a median value of 45. The general 
level of education was high, with a median of 13 years of completed schooling, ranging 
from 7-25 years. Neuropsychological assessments performed on subsamples of the entire 
cohort showed that mean IQ scores of study subjects were within the normal range 
(Vaskinn et al, 2007; Vaskinn et al, in press).  
 
AP drugs were prescribed to 73 % (N=302) of the patients, and 19 % (N=78) received two 
or more different APs. Antiepileptic mood stabilizers were prescribed to 31 % (N=130), 
lithium to 7 % (N=29), and antidepressants were prescribed to 35 % (N=146) of the 
patients. As much as 11% (N=47) of the patients received no AP, mood stabilizing, or 
antidepressant agent. These figures correspond well with other studies estimating standard 
drug regimes given to Norwegian patients with major psychoses (Johnsen et al, 2004). 
Jonsdottir et al, reported, in a newly submitted study on the present sample, that out of 255 
patients, 196 (77 %) had a 100 % self-reported adherence to medication. Of these subjects, 
158 (81%) had serum drug concentrations within the reference range, or higher, while 34 
(17 %) had serum concentrations below reference range, and only 4 (2 %) had non-
detectable serum concentrations The authors concluded that adherence rates were unusually 
high compared to other naturalistic studies on outpatients with SMI. 
 
6.1.2. Measurements 
Psychiatric assessments 
All assessments were made by a group of trained psychiatrists and clinical psychologists. 
Clinical interviews were performed, with additional information collected from treatment 
records to determine demographic factors, psychiatric history, medical history and current 
use of psychotropic medication, tobacco, alcohol and illicit drugs. 
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The Structured Interview for the DSM-IV Axis I Disorders (SCID-I) was used for 
diagnostic purposes (First et al, 1995). The SCID-I is a semi-structured interview, making 
use of all available information on the patient. In addition to direct information from the 
interviewees and the clinical staff responsible for treatment, the interviewers had access to 
the patient’s complete clinical file. All interviewers received training in use of the SCID-I, 
based on the training program at the University of California, Los Angeles (Ventura et al, 
1998). In addition, regular diagnostic consensus meetings were held, led by a well 
experienced clinical researcher in the field. To assess reliability, a random sample of 28 
cases was drawn, stratified to include an equal number of cases from every member of the 
assessment team. Anonymous vignettes describing symptoms and development of the 
illness were then rated by two experts blind to the study ratings. Inter-rater reliability was 
deemed to be highly satisfying, with an 82 % overall agreement on diagnostic categories 
and an overall  = 0.77 (95% C.I: 0.60-0.94).  
 
Psychosocial functioning was measured by the Global Assessment of Functioning Scale 
(Endicott et al, 1976), and the scores were split into scales of symptoms (GAF-S) and 
function (GAF-F) to improve psychometric properties (Pedersen et al, 2007). The inter-rater 
reliability was good with an intra class correlation coefficient (1.1) = 0.86 for both symptom 
and function GAF scores (Shrout and Fleiss, 1979). 
 
Psychiatric symptom ratings were done using the Positive and Negative Syndrome Scale 
(PANSS) (Kay et al, 1987). Inter-rater reliability was satisfying, with intra class correlation 
coefficients (1.1) = 0.73, 0.73 and 0.71 for PANSS positive, negative and general scores, 
respectively. In addition, the Inventory of Depressive Symptoms Scale (IDS) (Rush et al, 
1996) was used for assessment of depression severity level. 
 
Somatic assessments 
Physical examinations were performed immediately after the interview. Blood pressure 
(BP) was measured manually in a sitting position after resting, and body mass index (BMI: 
weight in kg/height in m2) was calculated by asking patients about their height and 
weighing them on calibrated digital weights wearing light clothing but no shoes. Waist 
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circumference was measured midway between the lower rib and the iliac crest in the upright 
position using a non elastic tape.  
 
Blood samples were drawn after an over-night fast of at least 8 hours and analyzed for 
fasting plasma glucose (FPG), total cholesterol (TC), high density lipoprotein cholesterol 
(HDL-C), low density lipoprotein cholesterol (LDL-C), and triglycerides (TGs). All serum 
analyses were performed at the Department of Clinical Chemistry, Ulleval University 
Hospital, on an Integra 800 (Roche Diagnostics), using standard methods. Serum or plasma 
levels of insulin, leptin and adiponectin were measured with radioimmunoassay (Linco 
Research, Inc, St. Charles, MO, USA), serum cortisol by  luminoimmunoassay, and Sex 
hormone binding globulin (SHBG) by immunoluminometric assay (Diagnostic Products 
Corporation, Los Angeles, CA, USA), all at the Department of Endocrinology, Aker 
University Hospital. The homeostasis model assessment of insulin resistance (HOMA-IR) 
was used to assess insulin resistance (IR) on the basis of the known relationship between 
FPG and serum insulin concentrations (Mathews et al, 1985). The HOMA-IR was 
calculated by the following formula: HOMA-IR = [(fasting insulin (pmol/L) x FPG 
(mmol/L) / 135]. Serum concentrations of antipsychotic drugs were analyzed at the 
Department of Clinical Pharmacology, St. Olavs Hospital, Trondheim. 
 
6.2 Reference material / the 2000-2001 Oslo Health (HUBRO) Study 
The population based HUBRO Study was conducted in Oslo from May 2000 to September 
2001 by the Norwegian Institute of Public Health in joint collaboration with the Oslo City 
Council and the University of Oslo. The aim of the study was to identify variables at the 
individual level to explain social inequality in health. The Regional Committee for Medical 
Research Ethics reviewed the study protocol and the Norwegian Data Inspectorate approved 
the study. All participants gave their written consent. More details about this study can be 
obtained from the Norwegian Institute of Public Health (www.fhi.no). 
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6.2.1. Subjects 
All citizens aged 30, 40, 45, 59-60 and 75-76 years were invited to attend the screening 
station located in the city center. Of the 40,888 citizens invited, a total of 18,770 individuals 
(46 %) participated in the survey. To match the age span of the TOP Study, only individuals 
in the age group of 30 to 60 years were included as a reference group in the present thesis, 
6879 men and 8307 women (Paper I & II). 
 
6.2.2. Measurements 
Information on age, gender, country of birth, and marital status was recorded from Statistics 
Norway (Oslo, Norway). All other information on demographic and health issue data was 
collected from questionnaires filled in by the participants. At the time of screening, a 
clinical examination was conducted according to a standard protocol. All participants were 
measured and weighed on electronic scales.  BP was taken using an automatic device 
(DINAMAP, Critikon, Tampa, FL). Nonfasting venous blood samples were taken for TC, 
HDL-C, TGs and glucose. Serum analyses were performed by the same methods and in the 
same laboratory as for the TOP Study.  
 
For the purpose of the present study we made use of the following demographic variables: 
age, gender, country of birth, country of birth of the parents, years of education, and marital 
status. We made use of the following self-reported health issue data: self-reported diabetes, 
use of diabetes medication, and daily smoking; and the following data from the clinical 
examination: BMI, BP, blood glucose and lipid levels. 
 
6.3. Sub-studies sampling procedures  
Details on the study sampling procedures are summarized in Figure 1 below. 
 
Paper I: 
For the purpose of investigating the CVD risk prevalence in a representative sample of 
patients with severe mental illness, we compared data from all patients included into the 
ongoing Ulleval 600 Study by May 2005 (205 pharmacologically stable outpatients with 
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DSM- IV psychotic or severe affective disorders), with reference data from subjects of the 
same age-group in the 2000-2001 Oslo Health Study (15,186 individuals from the general 
population of the same area). Subjects were stratified according to age and gender and 
compared for ethnic background, level of education, marital status, and prevalence of risk 
factors. The Ulleval 600 Study was later integrated into the larger TOP Study. 
 
Paper II: 
For the purpose of comparing CVD risk factors in schizophrenia and bipolar patients, we 
excluded all subjects with other diagnoses from the main sample included into the TOP 
Study by December 2005. Schizophrenia patients (n = 163) and bipolar disorder patients (n 
= 110) were then compared on sociodemographic variables, psychiatric symptom severity 
measures, prevalence of smoking, and age adjusted levels of metabolic risk factors. Current 
use of psychotropic medication was described for both groups. Finally, risk factors in both 
groups were compared with reference data from the general population (15,186 individuals 
from the 2000-2001 Oslo Health Study). 
 
Paper III: 
For the purpose of investigating the amount of cardio-metabolic risk that could be attributed 
to specific antipsychotic treatment in a naturalistic sample, we excluded all patients who 
were not on strict monotherapy with one single AP agent, or unmedicated, from the main 
sample included into the TOP Study by July 2006. Study subjects were then divided into 
three groups according to actual treatment with OLZ or CLZ (N=80), monotherapy with 
any other antipsychotic (N=80), or unmedicated (N=82). Groups were adjusted for age and 
compared for prevalence of the metabolic syndrome and its components. Groups were 
further adjusted for body mass and compared for mean values of BP, FPG, and lipids.  
 
Paper IV: 
For the purpose of investigating whether signs of hormonal dysregulation could be 
attributed to OLZ treatment in a naturalistic cross-sectional sample, we excluded all patients 
who were not on strict monotherapy with one single AP, or unmedicated, from the main  
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sample included into the TOP Study by July 2006. In addition, CLZ treated patients were 
excluded for reasons of representativity. Study subjects were divided into three groups 
according to actual treatment with OLZ (N=72), monotherapy with any other AP (N=80), or 
unmedicated (N=82). Groups were adjusted for age and BMI, and compared for HOMA-IR, 
fasting concentrations of FPG, insulin, adiponectin, and cortisol. Gender stratified analyses 
were performed for leptin and SHBG. 
 
Figure 1. 
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Figure showing the sampling procedure for the four individual sub-studies of this thesis. 
Abbreviations: U600: Ulleval 600; TOP: Thematic Psychosis Research Study; Sch: 
schizophrenia; BD: bipolar disorder; OLZ: olanzapine; CLZ: clozapine; AP; antipsychotics; 
No AP: currently unmedicated. 
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6.4. Statistical analyses 
All analyses were performed using the Windows SPSS software package for Windows 
version 12.01-14.01 (SPSS, Chicago, IL). Descriptive statistics were represented as mean ± 
SD or proportions for observed values, and as mean (95% C.I.) for adjusted values. 
Categorical demographic variables were compared using the Chi-square test, and 
continuous demographic variables were compared using one-way analysis of variance and 
independent sample t tests. Pairwise comparisons were only made if the P values were  .05 
in the overall group effect F tests. Two-sided tests were used. Log transformations were 
performed prior to statistical analyses for data that were not normally distributed, but data 
were given as real numbers for clarity. Univariate analyses of covariance were used to 
compare outcome variables across groups when adjustments were needed for differences in 
age and BMI. The strength of the linear relationship between two parameters was calculated 
using the Pearson correlation coefficient (r). The significance level was generally set to p  
.05. 
 
In Paper I, men and women were compared separately, first by comparing values for all 
patients to all controls, secondly by stratifying each gender into matching age-groups and 
comparing them separately. To avoid type I errors caused by a large N in this sub-study we 
used an a priori significance level of P < 0.01. To control for the effects of multiple 
comparisons in the metabolic variables we also did Bonferroni corrections, i.e. dividing the 
P value with number of within-group comparisons. In Paper IV, Leptin and SHBG were 
analyzed after stratification for gender, because of the large, gender-specific heterogeneity 
in these variables.  
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7. Results 
 
Paper I: 
Patients had an overall prevalence of CVD risk factors, such as smoking, obesity, 
hypertension, Low HDL-C and diabetes mellitus about twice that of the reference group. 
Hypertension was mainly due to increased diastolic BP in patients. Systolic BP did not 
differ significantly between the two cohorts. TC levels were only moderately elevated in 
patients. TGs and FPG could not be statistically compared, because fasting blood values 
were not available in the reference group. However, prevalences of high risk values, as well 
as mean values for TGs and glucose, although fasting, were higher than in the non-fasting 
reference group, with the exception of TGs in males. Patients aged 18 through 45 years had 
the highest level of risk factors when compared to the general population. There was no 
major difference in sociodemographic factors such as ethnic background or educational 
level between cohorts, although a significant higher number of patients were unmarried / 
living single. 
 
In conclusion, the CVD risk profile in this sample of Norwegian outpatients was alarmingly 
high, particularly in young individuals, and could not be explained by socio-demographic 
factors alone.   
 
Paper II: 
Patients with bipolar disorder had significantly higher levels of education, better social 
functioning, less psychiatric symptoms, and less use of AP medication than patients with 
schizophrenia. However, there was no significant difference in the prevalence of smoking, 
obesity, metabolic syndrome, or diabetes between diagnostic groups. Only mean levels of 
HDL-C was lower in schizophrenia (p<0.001), and systolic BP was higher in bipolar 
disorder (p<0.05). Both diagnostic groups had a prevalence of CVD risk factors about twice 
that of the general population. 
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In conclusion, the prevalence of CVD risk factors was very high, and approximately the 
same in bipolar disorder and schizophrenia. 
 
Paper III: 
There was no significant difference among treatment groups in the prevalence of obesity, 
hypertension, or hyperglycemia. The age adjusted prevalence of MetS was 24 % in the 
OLZ/CLZ group, 16 % in the Other AP group, and 12 % in the No AP group. However, 
these differences did not reach statistical significance. Despite similar BMI, OLZ/CLZ 
treated subjects had a significantly higher prevalence of dyslipidemia (high TGs and low 
HDL-C) than unmedicated subjects. They also had higher mean values of TGs (p=.003), 
and lower mean values of HDL-C (p<.001). Patients treated with other APs had 
intermediate values. 
  
In conclusion, adiposity and most other components of the MetS were equally distributed 
across treatment groups in this naturalistic sample. However, AP treatment, in particular 
with OLZ (and CLZ), was significantly associated with dyslipidemia, independent of body 
mass. This indicates a primary drug induced effect on lipid regulation which may be of 
importance in understanding AP mechanism of action. In addition, the findings have some 
important clinical implications, suggesting that lipid profiles should be monitored in all 
patients receiving AP agents. 
 
Paper IV: 
Trend-level differences for HOMA-IR (p=.051), and significant differences for fasting 
concentrations of insulin (p=.025), adiponectin (p=.017), and cortisol (p=.003) were found 
across groups. OLZ treated subjects had the highest HOMA-IR and insulin concentrations, 
and the lowest adiponectin and cortisol concentrations. Females had significant inter-group 
differences for SHBG (p=.001) and leptin (p=.005), with OLZ treated subjects having the 
lowest SHBG and the highest leptin concentrations.  
 
In conclusion, AP treatment, in particular with OLZ, was associated with alterations in 
several inter-related metabolic hormones, indicating insulin resistance independent of 
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obesity. Females had additional indications of resistance to leptin. The findings are in 
accordance with recent preclinical studies, suggesting that desensitizing to satiety signals 
may be a key mechanism for AP induced metabolic disturbances in humans.  
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8. Discussion 
 
The main finding of the present studies was an alarmingly high prevalence in the study 
sample of CVD risk factors, including smoking, obesity, hypertension, diabetes, 
dyslipidemia, and the metabolic syndrome. Risk was particularly increased in young 
subjects, and similar in bipolar and schizophrenia patients. High risk could not be explained 
by sociodemographic factors or current use of AP drugs alone. However, dyslipidemia and 
signs of insulin and leptin resistance were significantly associated with AP medication, in 
particular with the use of OLZ. Females seemed to be particularly at risk for developing 
cardio-metabolic disturbances. 
 
8.1. Discussion of results 
8.1.1. Prevalence of cardiovascular risk factors in patients with severe mental 
illness 
Our findings (Paper I) of an approximately two-fold increase in most CVD risk factors in 
patients with SMI compared to the general population are in accordance with other, recent 
studies (Heiskanen et al, 2003; Basu et al, 2004; Cohn et al, 2004; McEvoy et al, 2005; de 
Leon et al, 2005; Saari et al, 2005; Fagilioni et al, 2005; De Hert et al, 2006; Yumru et al, 
2007). Investigators report on largely increased prevalences of MetS and daily smoking in 
psychiatric patients across the European and Northern American continents, despite 
differences in sample characteristics regarding sociodemographic and clinical status. The 
findings are in line with epidemiological research showing that mortality from CVD in SMI 
patients is increased, and that the differential mortality gap compared to the surrounding 
population is rising (Saha et al, 2007). The findings thus have important implications for 
clinical practice. 
 
In agreement with other investigators, we also found that the relative prevalence of risk 
factors was highest in the youngest age group of patients (Paper I). The results correspond 
with the findings of Osborn et al (2007), that patients with SMI aged 18-49 years have a 3-
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fold mortality risk from CVD compared with the general population, while, with increasing 
age, the relative risk flattens out. In addition, there were indications in our study, as in 
others (Allison et al, 1999b; Homel et al, 2002; McEvoy et al, 2005; Hakko et al, 2006), 
that females with SMI are at particular risk of developing obesity and metabolic 
disturbances (Paper I-IV). 
 
One possible explanation for these findings may be that patients carrying the greatest risk 
have expired at a relatively young age, or young individuals may have been subjected to a 
more obesogenic lifestyle.  Another possibility is that young patients, to a larger degree than 
older, have been treated with SGAs, in particular with OLZ, which for several years has 
been the most frequently used AP drug in Norway. Homel et al (2002) reported, in a study 
on overweight among schizophrenic versus non-schizophrenic individuals in a nationally 
representative sample of the US adult population, that from 1987-1996, BMI increased 
dramatically among women with schizophrenia ages 18-30, relative to their non-
schizophrenic counterparts. This time period corresponds with the general introduction of 
the SGAs in the US. Interestingly, the same time trend was not found in males. The 
mechanisms underlying these findings remain unclear, but the authors speculate that 
metabolic side effects of the SGAs may be mediated by sex hormones. 
 
Population based surveys have consistently shown that CVD risk factors vary with 
sociodemographic background, in that the wealthy and well educated, often predominantly 
Caucasian, segments of the population, have a healthier life style, lower health risk, and a 
longer life expectancy than others. In our study, no demographic divergence was found 
between the study and reference sample that could readily explain the large difference in 
CVD risk (Paper I). Other authors, prior to and in parallel to our enquiries, have reached 
similar conclusions. Saari et al (2005) found no association between the presence of MetS 
and demographic or clinical variables. Furthermore, Brown (1997), Brown et al (2000), and 
Osborn et al (2007) did not find any explicit link between increased mortality in the 
mentally ill and signs of social deprivation, such as poverty, civil status, employment status, 
or social class.  
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The authors of the CATIE Study concluded that MetS was more prevalent in schizophrenia 
patients than in any other group studied (McEvoy et al, 2005). However, there have been 
reports on a raised prevalence of obesity and MetS in individuals with bipolar disorder as 
well (Elmsie et al, 2000; Fagilioni et al, 2002; McElroy et al, 2002; Fagilioni et al, 2005, 
Yumru et al, 2007). As far as we know, our study (Paper II) was the first to directly 
compare subjects from these two diagnostic groups on all the components of MetS. Despite 
significantly better social functioning and less psychiatric symptoms in bipolar versus 
schizophrenia patients, the distribution of CVD risk was almost the same across groups. 
These findings strengthen the conclusion that sociodemographic variables are not central in 
explaining somatic risk factors in individuals with SMI (paper I). Furthermore, the findings 
indicate that mechanisms beside adverse effects of APs are involved, since the prevalence 
of risk factors was the same across groups, despite a substantial lower use of SGAs in 
bipolar subjects.  
 
On the other hand, our findings are in line with recent population based studies showing 
mood disorders to be associated with obesity, type 2 diabetes and CVD (Simon et al, 2006; 
Engum, 2007; Fenton & Stover, 2006). One possible mechanism could be that chronic 
stress is related to severe affective disorders to a greater extent than to schizophrenia, 
causing  alterations in the regulation of the HPA-axis that would induce metabolic 
disturbances, including abdominal obesity and the MetS (Bjørntorp & Rosmund, 2000; 
Cowen, 2002). A very strong association has previously been shown to exist between 
hypertension and increased HPA axis activity (Bjørntorp & Rosmund, 2000), indicating 
high levels of hypothalamic arousal. In accordance with one parallel study (Johannessen et 
al, 2006), we found systolic BP to be significantly higher in bipolar than in schizophrenia 
patients. This seems to support the hypothesis that perceived stress may be etiologically 
linked to metabolic disturbances in severe affective disorders.   
 
In addition, there is accumulating evidence that feeding is not just a matter of energy 
homeostasis, but of emotional regulation (Saper et al, 2002; Kishi & Elmquist, 2005). In 
addition, disturbances in the circadian rhythm have been shown to effect metabolism in a 
negative way (Yin et al, 2007; Imaizumi et al, 2007). One could speculate that the 
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emotional dysregulation, and the disturbance in sleep pattern associated with bipolar 
disorder, may interfere with hunger and feeding mechanisms, leading to altered metabolism 
and obesity.  
 
8.1.2. Metabolic side effects of antipsychotic medication 
Besides BP, the only significant difference found between diagnostic groups (Paper II) was 
a lower level of HDL-C in schizophrenia subjects, most pronounced in women. The most 
plausible explanation for this finding was that medication differed greatly between the 
groups, with APs; OLZ in particular, being much more frequently prescribed to 
schizophrenia subjects. In addition, a large number of bipolar patients were currently 
unmedicated.  
 
We explored this question by investigating the presence of metabolic risk variables in 
subjects on current monotherapy with OLZ (or CLZ) compared with other APs, using 
unmedicated patients as a control group (Paper III). Our findings were mainly in accordance 
with other reports published during the progress of our investigation, using a similar cross-
sectional and naturalistic design. These studies investigated the prevalence of MetS (De 
Hert et al, 2006), diabetes and insulin resistance (Cohen et al, 2006), and hyperlipidemia 
(Smith et al, 2005; de Leon et al, 2007) across groups of patients treated with different APs. 
None of the investigators found significant differences in body mass, BP, MetS, or 
hyperglycemia across treatment groups. One explanation for this may be that clinicians tend 
to select drug treatment according to the somatic health risk profile of their patients, and 
avoid prescribing OLZ and CLZ in the presence of obesity, or any diagnosed metabolic 
disorder (de Leon et al, 2007). 
 
Interestingly, one recently published, randomized and prospective study on drug naïve first 
episode patients, reported a substantial weight gain after 12 months of AP monotherapy in 
all subjects, but no significant difference was found between treatment with OLZ, 
risperidone, and haloperidol (Perez-Iglesias et al, 2007). The results seemed to mimic the 
observation by Planansky (1958), referring to the recently introduced drug chlorpromazine, 
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that all treatments showing effect in previously untreated, psychotic subjects are 
accompanied by weight gain. 
 
On the other hand, our finding of significantly raised levels of TGs in OLZ treated subjects, 
independent of body mass, were in accordance with the results of Smith et al (2005) and de 
Leon et al (2007). However, none of these investigators reported on a decreased level of 
HDL-C, which was the most striking finding in our study. One reason for this discrepancy 
may be that co-medication with drugs other than APs were allowed in these studies, while 
subjects in our sample were on strict monotherapy. Another, equally or more important 
reason, could be that especially Smith et al, but also de Leon et al, had very few females 
included in their OLZ treatment group. Within our sample, low HDL-C was most 
pronounced in women, and after gender stratification and adjustment for both age and BMI,  
HDL-C in females was the only variable still significantly lower in OLZ treated than in 
unmedicated subjects (p=.006) 
 
High levels of TGs combined with low levels of HDL-C are associated with insulin 
resistance and with increased risk for CVD (McLaughlin et al, 2003; Linsel-Nitschke & 
Tall, 2005; Semenkovich, 2006). This constellation, often named atherogenic dyslipidemia, 
is in normal subjects significantly correlated to visceral obesity. In our sample, this 
correlation was consistently found only in drug free patients. The findings indicate that 
some APs induce dysregulation of lipid metabolism independent of weight gain, and that 
females are most susceptible to this side effect of medication.  
 
In humans, information from adipose tissue and nutrients is processed by the hypothalamus 
to maintain stable body weight through regulation of appetite, and to maintain stable levels 
of circulating glucose and lipids through regulation of the endogenous production in liver. 
This regulatory pathway, sometimes referred to as the “fat-brain-liver axis”, is mediated 
through a complicating interplay of hormones (Birkeland et al, 1993; Newcomer et al, 
1998; Gabay & Kushner, 1999; Söderberg et al, 2001; Obici et al, 2002; Cnop et al, 2003; 
Cikim et al, 2004; Elmquist & Flier 2004, Schwartz & Porte 2005, Weinberg et al, 2006; 
Whitehead et al, 2006; Lam et al, 2007). AMPK, often described as a cellular fuel sensor, is 
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a central component in the energy homeostasis network of the “fat-brain-liver axis” 
(Minokoshi et al, 2004). Satiety signals, such as the hormones leptin and insulin, suppress 
the activity of AMPK in various parts of the hypothalamus, inducing appetite loss and 
downregulation of the endogenous production of nutrients. Lack of AMPK suppression has 
been shown to cause leptin resistance, with resulting hyperphagia (Minokoshi et al, 2004), 
as well as central insulin resistance, causing an increased endogenous production of TG-rich 
lipoproteins and glucose in the liver (Obici et al, 2002; Lam et al, 2007).  
 
Throughout the progress of our investigation, preclinical and human studies had 
demonstrated that OLZ treatment influence on the regulation of metabolic hormones central 
to maintenance of energy homeostasis (Newcomer et al, 2002; Henderson et al, 2005; Ader 
et al, 2005; Albaugh et al, 2006; Richards et al, 2006; Sacher et al, 2007; Houseknecht et 
al, 2007). In addition, Kim et al (2007) had demonstrated, in a rat model, that these effects 
could be explained by OLZ affecting the regulatory function of AMPK in the 
hypothalamus. Encouraged by these findings we investigated if differences in a range of 
metabolic hormones would be present across treatment groups (Paper IV). 
 
Our findings of high HOMA-IR, along with high levels of fasting insulin, and low levels of 
adiponectin in OLZ treated subjects, independent of body mass, are in accordance with 
previous studies (Newcomer et al, 2002; Henderson et al, 2005; Richards et al, 2006; 
Sacher et al, 2007), and indicate OLZ induced insulin resistance. This relationship is further 
strengthened by the correlations found between serum concentrations of OLZ and levels of 
HOMA-IR and insulin (Paper IV).  
 
Our findings of high fasting levels of leptin in normal weight females, indicative of leptin 
resistance, seem more controversial. Leptin resistance has been proposed as one possible 
mechanism of OLZ induced hyperphagia and weight gain in a rat model (Kim et al, 2007), 
but previous clinical studies have yielded conflicting results (Henderson et al, 2005;  
Melkersson & Hulting, 2001; Hägg et al, 2001; Haupt et al, 2005; Smith et al, 2005). 
However, negative findings in some trials may have been due to a liberal use of co-
medication allowed across treatment groups, and to the fact that very low numbers of 
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female subjects were included. Drugs other than APs could have independent effects on 
hormonal regulation, and leptin is known to be highly dependent on gender. Preclinical 
studies have shown that female rats are particularly vulnerable to hyperleptinemia and 
hyperphagia in response to OLZ treatment (Albaugh et al, 2006).  
 
The present finding of increased leptin concentrations in OLZ treated females only may be 
due to the low age of most women in the TOP Study sample. Leptin and testosterone levels 
are known to correlate directly in premenopausal non-obese women (Söderberg et al, 2001), 
and this was also the case in our sample. We can only speculate that  OLZ induced effects 
on androgens may contribute to a gender specific leptin resistance, which may contribute to 
the observation that female patients seem particularly vulnerable to develop obesity in 
response to antipsychotic treatment (Allison et al, 1999b; Homel et al, 2002; McEvoy et al, 
2005; Hakko et al, 2006). 
 
To our knowledge, no previous study has reported on decreased levels of circulating 
cortisol in association with OLZ treatment. Nevertheless, this finding is not surprising, since 
OLZ has a well documented sedative effect. However, low cortisol levels would be 
expected to protect against the development of insulin and leptin resistance (Newcomer et 
al, 1998; Bjorntorp & Rosmond, 2000). Our findings thus indicate that OLZ induced 
resistance to “satiety signals” occurs independent of body mass, and despite lower stress 
hormone levels.  
 
Finally, to our knowledge, this is the first study suggestive of OLZ induced hepatic insulin 
resistance in humans, although this effect has been reported independent of weight gain in 
animal studies (Ader et al, 2006; Houseknecht et al, 2007). Our findings of a significantly 
increased TG/HDL-C ratio in OLZ treated patients, along with low SHBG and adiponectin 
levels, is indicative of an hepatic failure in suppressing the production of triglyceride-rich 
lipoproteins in the presence of elevated circulating insulin. Plasma glucose, on the other 
hand, will remain stable as long as the pancreatic production of insulin and the disposal of 
glucose by skeletal muscle remain adequate.  
 
47 
 
8.2. Discussion of methodological issues 
8.2.1. Study and reference sample 
The total clinical study samples comprised all patients included in the ongoing TOP Study 
at consecutive points of time (May 2005, December 2006, and July 2006). For the purpose 
of each sub-study, a lesser number of subjects were selected according to specific criteria. 
The number of individuals thus subjected to further investigation in each sub-study was: 
N=205 (Paper I), N=273 (Paper II), N=242 (Paper III), and N=234 (Paper IV). In Paper I 
and II, the study samples were compared with reference data from the population based 
HUBRO Study, comprising a total of 18,770 individuals. Only reference data for 
individuals within the age-interval of the TOP Study sample were considered (N=15,186). 
 
Representativity 
The inclusion area for the clinical TOP Study, as for the population based HUBRO Study, 
covered practically the whole city of Oslo. Psychiatric services in Norway are catchment 
area based and publicly funded. Outpatient clinics are equally distributed and offer a similar 
quality of care across all districts of the city, regardless of socio-economic and socio-
cultural differences. Both study samples represented unselected cohorts, which were 
examined within a corresponding time interval of approximately four years, assuring 
concordance in time for variables susceptible of rapid changes within any given society.  
 
Surveys on health equity are often hampered by selection bias due to low rates of 
participation among the invitees. In the HUBRO Study, the participation rate was 42.4 % in 
men and 49.3 % in women. As expected, information from the non-responders was 
insufficient to directly quantify the bias. However, non-responders could be traced, and an 
evaluation of the selection bias was made after linking public registers in Statistics Norway 
and the HUBRO Study (Søgaard et al, 2004). The authors found that response rates were 
positively correlated with age, level of education, total income, female gender, married 
status, born in a Western country, living in the outer city residential regions, and not 
receiving disability benefit. However, self-selection according to socio-demographic 
variables had little impact on prevalence estimates. Unhealthy persons attended to a lesser 
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degree than healthy individuals, but social inequality in health by different socio-
demographic variables seemed unbiased.  
 
As for the TOP Study, there was no possibility of tracing patients with relevant diagnoses 
who had not been included, since Norway, unlike other Scandinavian countries, does not 
have a national Hospital Discharge Register with available diagnoses. Due to the person 
data security act, information on invitees declining to participate was inaccessible. It was 
thus not possible to estimate the participation rate. However, some degree of selection bias 
must be assumed. Very impaired patients, lacking capacity of informed consent, would not 
be approached. It also seems likely that individuals suffering from severe cognitive deficits, 
massive negative symptoms, or paranoid ideation, would tend to decline participation, even 
when invited, or may not be capable of completing the inclusion procedures. In addition, the 
TOP sample was biased towards young subjects with a short duration of illness, since part 
of the total study focuses on first episode psychosis. 
 
As one mean of estimating the representativity of the present clinical sample, we compared 
data from the TOP Study with accessible variables from the Ulleval 600 Health Care Study, 
a survey of all patients from the Department of Psychiatry, Ulleval University Hospital 
(constituting the largest and most heterogeneous health care sector of Oslo), conducted in 
the same time interval and comprising a total of 1002 subjects with ICD-10 F20-F39 
diagnoses (psychoses and severe, affective disorders). Among these patients, 53 % (528) 
were male, and 47 % (474) were female. Mean (SD) age was 39.2 (12.8) years, and median 
age 38 years, ranging from 16-82 years. Mean (SD) symptom GAF was 40.2 (13.4), median 
value 38, ranging from 1-85. Mean (SD) function GAF was 40.3 (12.9), median value 39, 
ranging from 1-85. As described by Ringen et al (in press), the prevalence of illicit drug use 
in these two partially overlapping samples was almost identical (15.5 versus 15.2 %). 
However, TOP Study patients were younger (median age 32 versus 38 years), and had 
somewhat higher GAF scores than the Ulleval 600 Health Care Study sample (median 
values 45/45 versus 38/39). 
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From the descriptive data given in the Methods section, and from the comparison with the 
Ulleval 600 Health Care Study, we conclude that the TOP Study sample was representative 
of relatively young and ethnically homogenous individuals with verified diagnoses of 
psychotic or severe affective disorder, studied under real life conditions while receiving 
“treatment as usual”. The majority of the cohort was outpatients, with a short duration of 
illness, a relatively high level of functioning, and very good adherence to medication. 
Furthermore, the sample had IQ-levels within the normal range, and an educational level 
equalling that of the general population (http://www.fhi.no). The confounding effects of 
hospitalization, long term treatment, and impaired cognitive and social functioning, were 
thus minimized, making comparison with a community sample more valid. In contrast to 
most other, recent studies in this field of interest (McEvoy et al, 2005; De Hert et al, 2006) 
reference data were collected from the general population of the same restricted 
geographical and socio-cultural area within a limited time-span, thus avoiding falsely 
enlarged differences between patients and controls because of the temporal trends towards 
more overweight and metabolic disturbances in the overall population. 
   
Ethical aspects and patients perspective 
Ethics had a special relevance in this project as it implied research involving sensitive 
personal information and use of biological materials from patients with severe psychiatric 
disorders. The potential ethical aspects of the research were paid attention to regarding its 
objectives, the methodology and the possible implications of the results. The central issue 
was that of informed consent and confidentiality – that participants knew how their 
information and blood samples would be used, and that measures to ensure confidentiality 
were secure.  
 
The TOP Study was carried out in adult individuals, capable of giving informed consent. 
The clinical investigators in co-operation with the clinician in charge of treatment were 
responsible for assessing if individual patients were competent of giving consent. 
Individuals judged unable to consent were not included, nor were patients with below the 
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normal IQ range, or those not capable of speaking and understanding a Scandinavian 
language. No therapeutic clinical trials and no placebo therapy were proposed.   
 
All data collection was performed with the approval of the Regional Ethics Committee (ref 
# 493-03-01179), and written informed consent was obtained prior to study participation. 
The following procedures were followed: Each participant had the study explained by a 
health professional (medical doctor or psychologist) and received a written explanation 
covering: the purpose of the study, the extent of investigations and interviews, personal 
information to be stored, how confidentiality would be maintained, and when the project 
would end (database deleted and blood samples destroyed). Patients were explicitly 
informed; both in oral and in writing, that participation in the study was voluntary, and that 
refusal to participate would have no consequence for their future treatment. They were also 
informed of their right to see all data registered on them, and have their data and blood 
samples destroyed at any occasion. The collection and handling of data were approved by 
the Norwegian Data Protection Agency (ref # 2003/2052) to preserve the personal privacy 
of the participants. In addition, the TOP database was inspected and approved by the 
Clinical Monitor at Ulleval University Hospital. All personal information was treated with 
the same confidentiality as required within the EU countries medical system, and the only 
persons with access to personal information will be health care professionals with a duty of 
confidentiality. All personal identifiers were removed, and only a code was used as 
identifier. This code was stored in similar security level as ordinary patient data at the 
hospitals. Most biological samples used for clinical biochemistry and hormonal analyses 
were sent directly to the laboratories using the same procedures and protocols as ordinary 
clinical samples. However, for some hormonal analysis, the biological samples were stored 
in the TOP Biobank, which is a registered research biobank approved by the Norwegian 
Ministry of Health (ref # 200403453).    
 
Participants did not receive compensation for their participation, but in some cases 
transportation between the participants’ home/work place and the sample collection facility 
was provided. People suffering from SMI are often concerned with somatic health issues 
related to weight, physical fitness, smoking, and the risk for developing diabetes and 
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cardiovascular disease. Through the TOP Study, we performed clinical interviews with a 
focus not only on psychiatric symptoms, but on the general medical situation of patients, 
including lifestyle and adverse effects of pharmacological treatment. All subjects benefited 
from a thorough clinical assessment, which was reported to the physician in charge of their 
treatment. In addition, participants had the opportunity to ask any questions they wanted 
about the study, about their specific disease state, or about health issues in general. Many 
participants profited from this opportunity, explicitly commenting that the focus on somatic 
issues within the study has been “meaningful and important”, had made them feel “secure 
and well tended to”, and inspired quite a few to make major improvements in their smoking, 
dietary and exercise habits. A large number of patients also expressed a need for better 
somatic screening and a closer follow up on medication and life style issues within the 
general health system. Throughout the study, we, as clinical investigators, were impressed 
by the interest, co-operability and tenacity of the participants, without which this research 
would not have been possible.   
 
8.2.2. Assessments 
Psychiatric assessments 
The instruments employed for assessing psychiatric diagnoses, symptoms, and levels of 
functioning in the TOP Study are well recognized for use in clinical psychiatric research. 
The SCID-I interview is known to yield highly reliable diagnoses of Axis I disorders (Segal 
et al, 1994), and is considered to be the golden standard of diagnostic assessment. Likewise, 
the widespread use of the PANSS scale is based upon its excellent psychometric properties 
for assessing psychotic symptoms (Kay et al, 1987). The GAF Scale constitutes the axis V 
of the present DSM-IV diagnostic system, and has achieved worldwide status as a primary 
instrument for assessing change in psychiatric symptoms and functioning. Although its 
reliability in clinical settings has been questioned, it has proven highly satisfying in research 
situations (Vatnaland et al, 2007). 
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The TOP investigators were all clinically experienced psychologists or psychiatrists. They 
received ongoing supervision and participated in regular consensus meetings. A high 
standard was ascertained by senior researchers responsible for training and supervision, 
several of whom had previously taken part in projects involving an international network of 
co-workers, focusing on diagnosis and assessment of schizophrenia patients (Melle et al, 
2004). In addition, all clinical investigators underwent an extensive and structured training 
program led by a well recognized American researcher within the field of diagnostics 
(Ventura et al, 1998). To assure inter-rater reliability of the test battery employed, testing 
was performed, yielding very good to excellent results. 
   
Somatic assessments 
Somatic examinations of TOP patients were performed by physicians according to a 
standard protocol, as described in the Methods section. The procedures were the same as for 
the HUBRO Study, with the exception for BP being measured manually in the TOP (mean 
value of three measurements after at least 10 minutes rest), and digitally in the HUBRO 
Study. Blood samples in the TOP Study were drawn by one specially trained project nurse. 
All blood samples were collected between 8.00 and 12.00 a.m., after at least eight hours of 
fasting. The HUBRO Study blood samples, on the other hand, were drawn at random time 
points, and were non-fasting.  
 
The clinical chemical and hormonal analyses from the studies included in this thesis were 
performed at the Department of Clinical Chemistry, Ulleval University Hospital and the 
Hormone Laboratory, Aker University Hospital. The services of these laboratories are 
subject to regular internal precision and accuracy controls and both national and 
international quality controls in accordance with the recommendations of the Nordic 
committee on Quality Control of the Scandinavian Society for Clinical Chemistry. The 
departments participate in several external quality assessment schemes. The departments are 
working on accreditation and their quality systems are based on the general requirements 
for the competence of testing and calibrating laboratories.  
 
53 
 
8.2.3. Generalizability of findings 
The city of Oslo is a modern, West European capital, with a social security system covering 
all inhabitants. The population is ethnically quite homogenous. All patients with SMI have 
the right to psychosocial and medical treatment free of charge. The great majority of 
individuals with psychotic disorders receive help from the public specialist outpatient 
clinics at one time or another. Most of these patients have the right to a disability pension 
and/or community housing. There are very few homeless people among them (Melle et al, 
2000).  
 
The first aim of this thesis was to compare CVD risk in mentally ill patients with the 
general population. We found that our setting would greatly minimize the risk of possible 
confounders seen in other studies, where chronicity (Cohn et al, 2004; McEvoy et al, 2005), 
limited sample size (Heiskanen et al, 2003; Saari et al, 2005), or single site inclusion (De 
Hert et al, 2006) could have hampered the results. Psychiatric and somatic assessments 
were shown to hold a satisfying standard, and the reference data were adequate. As 
estimates of increased risk are relative entities, we concluded that our findings would be 
generalizable to similar patient populations in other parts of the Western world. It seems 
likely that the increased CVD risk seen in this sample of relatively young and high 
functioning patients receiving an adequate standard of care and social security, would be 
even more pronounced in severely impaired patients living under less fortunate 
circumstances, as well as in patients of ethnic groups known to have a greater vulnerability 
for metabolic disturbances than Caucasians.  
 
Our second aim was to compare CVD risk in patients belonging to one of the broad 
diagnostic categories of schizophrenia or bipolar disorder, which are both heterogeneous in 
their clinical appearance. The general level of functioning in bipolar disorder is usually 
better than in schizophrenia, although often highly state dependent. In the TOP Study 
sample, both diagnostic groups were included in a stable phase of disease, thus avoiding the 
confounding factors of stress intrinsic to acute psychotic or affective episodes. All subjects 
were nonetheless included from the same sites (predominantly outpatient clinics), 
implicating a continued need for specialist treatment. As expected, bipolar patients had 
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ratings for all background variables somewhere between the schizophrenia group and the 
general population. The comparison of the two groups was thus considered valid, reflecting 
the real difference in impairment normally found between individuals within these two 
diagnostic entities, and implicating that the findings of equal CVD risk was also 
generalizable to other settings. 
 
The further aim of the present thesis was to investigate if treatment with any specific AP 
agent could be associated with metabolic abnormalities. Efficacy and side effects of APs 
usually tested in prospective, randomized studies, but these drug trials are often limited by 
highly selected samples, a short time span, and high rates of discontinuation. For more 
representative findings, naturalistic studies have been warranted. These, on the other hand, 
have often investigated chronic patients, where adverse lifestyle and lingering effects of 
previous medication could have influenced the results. Confounding factors such as non 
adherence, and co-medication with drugs other than APs, are rarely controlled for. In 
addition, there has been a striking lack of appropriate control groups in previous naturalistic 
reports. 
 
Our investigation was performed on a representative sample of relatively young outpatients, 
under real-life conditions. From the total cohort, all subjects receiving AP treatment in 
monotherapy were selected, and divided into two subgroups:  (1) All patients currently on 
OLZ (or CLZ), and (2) all patients currently on any other AP agent. The rationale for 
including several APs in the comparison group, despite a high degree of heterogeneity 
among them, was to increase statistical power. Furthermore, because of a lesser propensity 
to cause weight gain, they are often used as alternatives to OLZ in clinical practice.  
Subjects treated with co-medication of other drugs known or suspected to induce weight 
gain were not considered. The rationale of this procedure was to avoid the confounding 
effects of co-medication, which usually hamper naturalistic studies. In addition, all patients 
not currently receiving any drug treatment were uses as a control group, to rule out, as far as 
possible, the effects on metabolism of the disease itself. All subjects (except two) had been 
on their present medication regimens, or unmedicated, for at least 4 weeks, and adherence 
was controlled for by measurements of AP serum concentration. 
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8.2.4. Strengths and weaknesses of the studies 
The studies included in this thesis had several strengths. The work was financially 
supported by public grants and was independent of sponsorship from the pharmaceutical 
industry. A naturalistic design was chosen, with a multi-site approach, and broad inclusion 
criteria, permitting us to gather information on a representative sample of individuals 
receiving “treatment as usual”. The study had sufficient power to obtain statistically 
significant answers to clinically important questions, also after stratification for gender.  
The sample was well characterized, and reliability testing was performed for all central 
items. Subjects were relatively ethnically homogenous and overall young, with a short 
duration of treatment and a high general level of functioning, thereby reducing the 
confounding effects of ethnicity,  long term hospitalization, and chronic disability. 
Moreover, subjects were generally in a stable phase of disease, limiting the uncertainty of 
whether findings should be ascribed to “state versus trait”. Most subjects were on stable 
medication, and adherence was ascertained by measuring serum concentrations of all 
psychotropic drugs prescribed and of interest to the study. Complete medication history was 
obtained for practically all participants, thereby minimizing the confounding effects of 
previous medication.  
 
In addition, reference data were collected from the general population of the same restricted 
geographical and socio-cultural area within a limited time-span, thus avoiding falsely 
enlarged differences between patients and controls because of the temporal trends towards 
more overweight and metabolic disturbances in the overall population. The HUBRO 
reference material thus had obvious advantages as compared to most other parallel 
investigations, including the CATIE Study. 
 
However, the studies had some weaknesses. The cross-sectional design was not fit for 
drawing conclusions about causality, and the sample was not large enough for doing 
elaborate analyses on subgroups of interest. In addition, waist circumference was not 
obtained for the first 200 patients included in the TOP Study. Waist circumference is 
generally considered a better measurement for central obesity than BMI, and thus a stronger 
indicator of elevated CVD risk, particularly in women. Waist circumference is also one of 
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the AHA/ NHLBI criteria for MetS. We were obliged to use BMI as an alternative obesity 
measure for the whole sample in Paper I, and BMI as an alternative measure for part of the 
sample in Paper II-IV. As a consequence of this, prevalences of obesity and MetS were 
probably underestimated in our studies as compared to others, particularly for women. 
Furthermore, the lack of fasting blood samples in the HUBRO material hindered us from 
properly comparing TG and FPG between the clinical and the reference sample, and we did 
not have access to reference data for prevalences of MetS in the general population. 
 
All substudies would have profited from direct information on important lifestyle issues, 
such as diet and physical activity. Instead, epidemiological data were used as indirect 
indicators of lifestyle in Paper I-II.  In Paper III-IV, both treatment groups and controls 
were made up of patients with SMI, who were similar in clinical psychiatric characteristics, 
thereby minimizing lifestyle differences due to the disease state itself. An additional 
weakness of Paper II was the lack of data on previous psychotropic medication. This was, 
however, compensated for in Paper III-IV.  
 
8.3. Clinical implications 
The findings have some important clinical implications. First of all, CVD risk should be 
taken seriously for all patients suffering from SMI. In Norway today, a systemic separation 
exists in the provision of public mental health and general health care, thereby posing a 
barrier to accessing primary medical services (Levinson Miller et al, 2003). Hence, 
psychiatric personnel of all categories must be aware of the somatic risk involved in severe 
mental disease. Alongside standard psychiatric treatment, there should be a much stronger 
focus on lifestyle interventions, including smoking cessation programs, dietary counselling, 
and physical activity. These issues need to be effectively addressed from the patient’s very 
first contact with the specialist psychiatric services. As young individuals seem to be 
carrying the largest amount of CVD risk, prevention should be given high priority. In 
addition, a joint effort is necessary to make detection and treatment of somatic risk factors 
and illness more available to psychiatric patients. Since public mental health services are 
clearly underserved concerning medical expertise, general community practitioners must be 
included in the assessment, monitoring, and treatment of high risk individuals. 
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When choosing AP medication, it is important to balance clinical gain against unwanted 
side effects, particularly for long term treatment. Somatic history and family anamnesis 
should always be taken prior to instigation of antipsychotic medication. In addition, 
physical exams should be performed, including measurement of weight, waist 
circumference, BP, and fasting blood tests.  After instigation, patients should be carefully 
monitored and new exams performed on a regular basis. There are today no official 
logarithms for monitoring of physical health in SMI patients in Norway. Standardized 
recommendations are clearly needed. It must be underscored that obesity as the sole 
parameter of metabolic disturbances not sufficient. Our data clearly demonstrate that 
dyslipidemia, hypertension and insulin resistance are equally important risk factors, also in 
patients who maintain normal weight. We argue that regular monitoring is needed for all 
SMI patients, regardless of diagnosis, medication, and body mass. 
 
 In addition, our findings indicate that female patients are particularly at risk for developing 
obesity and diabetes as a complication to SMI, and that they may be more susceptible than 
men to the metabolic side effects of antipsychotic treatment. Women’s health should 
therefore receive a renewed focus also within psychiatry, and special care taken when 
treating women with psychotropic medication.  
 
8.4. Implications for further research 
The increase in metabolic abnormalities found in patients with SMI cannot be ascribed to 
side-effects of SGAs alone. There is convincing evidence that disease specific factors other 
than medication are involved. Further studies are clearly needed to elucidate a possible 
covariance in the genetic susceptibility for developing SMI and metabolic disturbances. 
Since the heredity of both conditions is complex and must involve genes on several 
different loci, genome-wide studies on large scale samples are warranted. 
 
There is previous evidence that the prevalence of type II diabetes is increased in 
schizophrenia subjects as well as in their otherwise healthy relatives (Mukherjee et al, 
1989). On the other hand, type I diabetes has recently been shown to be inversely associated 
with schizophrenia (Juvonen et al, 2007). An interesting finding in our sample was the 
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exceedingly high prevalence of diabetes mellitus in women with bipolar disorder, although 
not conclusive because of small numbers. Of bipolar females, 8.6 % (5/61) had diagnosed 
diabetes, with 4.9 % (3/61) being type 1. Epidemiological, register based studies should be 
undertaken to examine the prevalence of type I diabetes in bipolar disorder. An interesting 
hypothesis is that a joint susceptibility for type I diabetes and psychosis may modify the 
phenotype of the mental disorder in a more affective direction, particularly in women. 
Hence, this is also an issue of interest for genetic investigation.  
 
The issue of gender clearly needs to be further investigated. There are indications 
throughout our study, as well as in previous and parallel reports (Homel et al, 2002; 
Seeman, 2004; McEvoy et al, 2005; Hakko et al, 2006) that females with SMI are more at 
risk than males of developing overweight and other metabolic disturbances. This may be the 
result of a gender specific susceptibility to AP related side effects, perhaps in combination 
with other factors (genetic, hormonal, or environmental). Until recently, women’s health 
has not been properly focused within psychiatric research, and clinical guidelines have often 
been based upon findings in predominantly male samples. There is an urgent need for 
prospective studies with sufficient power to investigate the effect of gender on somatic risk 
factors in psychiatric populations. 
 
Hormonal regulation is an important topic in elucidating the molecular basis of metabolism, 
included drug induced side effects. Recently, there has been large progress in the 
understanding of how metabolic homeostasis is maintained. However, there are important 
obstacles to the investigation of centrally regulated processes in humans, and findings are 
mostly based on preclinical studies. However, since there is evidence that hormones 
involved in the “fat-brain-liver” axis may play a role in the metabolic abnormalities 
associated with SMI, a first step should be to compare concentrations of these hormones in 
representative psychiatric and healthy samples, matched for most possible contributing 
variables, such as age, gender, ethnicity, and body mass composition. 
 
Metabolic homeostasis has been shown to be coordinated by circadian rhythms in plants 
and animals (Yin et al, 2007; Imaizumi et al, 2007). A fascinating new area of research 
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would be to study whether the sleep disturbances often associated with SMI, and in 
particular with bipolar disorder, could be linked to the development of hormonal 
dysregulation and metabolic disturbances. In order to do so, one would ideally need a well 
characterized sample of patients undergoing the different stages of bipolarity, and, if 
possible, followed prospectively from onset of their first affective episode. 
 
To further elucidate the mechanisms of how different APs effect metabolic regulation, 
studies are needed in medication naïve first episode patients. A broad variety of parameters 
should ideally be measured at baseline, and after stabilization on AP monotherapy. In 
addition to investigation of FPG, lipids, hormones, and anthropometric variables, RNA 
from blood cells should be collected for microarray analysis, since there are indications that 
APs activate the expression of lipid biosynthetic genes in human cells, both in vitro and in 
vivo (Ferno et al, 2005; Ferno et al, 2006; Vik-Mo et al, in press). Parallel ratings of 
psychiatric symptom must furthermore be performed to investigate the hypothesis that 
weight gain and clinical effect on psychotic symptoms may somehow be related (Planansky, 
1958; Procyshyn et al, 2007). 
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9. Conclusions 
 
• Norwegian patients with SMI had an alarmingly high prevalence of CVD risk 
factors compared to the general population. 
• Young patients (18-45 years) had the largest relative increase in CVD risk. 
• Females had a particular high prevalence of obesity and diabetes. 
• The increase in CVD risk factors could not be explained by socio-demographic 
factors alone. 
• The increase in CVD risk factors was approximately the same in bipolar disorder 
and schizophrenia. 
• Antipsychotic treatment, in particular with OLZ (and CLZ), was significantly 
associated with dyslipidemia, independent of body mass. The findings were most 
pronounced in females. Other components of the MetS were not significantly 
associated with any particular antipsychotic agent in this naturalistic setting.  
• Antipsychotic treatment, in particular with OLZ, was associated with alterations in 
several inter-related metabolic hormones, indicating insulin resistance independent 
of obesity. Females had additional indications of resistance to leptin.  
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10. Errata 
 
The printed version of this thesis is a reprint of the originally submitted thesis to the University of 
Oslo. One additional paper has now been published; Paper III in Journal of Clinical 
Psychopharmacology.  
 
The following changes (seen in bold) have been made: 
 
1) Thesis 
Chapter 2. List of papers: 
Paper III: Correct reference is J Clin Psychopharmacol 2008;28(2):132-137. 
 
2) Paper II 
Methods section, page 918, paragraph 3, is written “intraclass correlation coefficients = 0.86, df 1.1, 
for both symptom and function GAF scores”. This is not correct, and should be substituted by ICC 
(1.1), referring to the first of six intraclass correlations described by Shrout & Fleiss (1977). The 
first number 1 means that the actual raters are considered as one sample of possible raters, while the 
second number 1 means that the reliability of single scores is assessed (in contrast to the mean of the 
scores by several raters). This has nothing to do with “degrees of freedom”.  
 
3) Paper III 
a)  Results section, page 134, Figure 1:  
OLZ/CLZ, n = 80. *P < 0.01, †P  0.001.  
Last line, legend: “…Other AP, patients treated with monotherapy of any other AP; No AP, drug-
free patients.” 
 
b) Results section, page 135, paragraph 1:  
Finally, TG/HDL-C was significantly higher in group OLZ/CLZ versus group No AP (p<.001) and 
in group Other AP versus group No AP (p<.05). 
 
c)    Reference section, page 137, reference 35:  
WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification 
and DDD assignment 2007. Norwegian Institute of Public Health. Oslo, 2006. 
 
 
4) Paper IV 
Methods section, page 12, paragraph 1:  
HOMA-IR = [(fasting insulin (pmol/L) x FPG (mmol/L) / 135]. 
 
 
Oslo, July 2008 
Astrid B. Birkenæs 
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